Tag: DAGL inhibitor

Split-screen comparison of enzyme inhibitor effects: Day 1 shows dramatic metabolic improvements (53% insulin drop, 23% reduced food intake) when DAGL and NAPE-PLD are blocked, but Day 7 reveals complete failure as arachidonic acid substrate reroutes to inflammatory COX/LOX pathways, causing weight rebound, inflammation, and glucose dysfunction

The Enzyme Inhibitor Paradox: Why Anti-Obesity Drugs Keep Failing

Posted on October 19, 2025October 19, 2025 By Stefan Broselid

A new study just proved something remarkable: researchers found a way to slash insulin levels by 53% in just two hours. Food intake dropped 23%. Body weight fell within 24 hours. The pharmaceutical industry should be celebrating. Except there’s a problem. By day seven, it stopped working. Completely. The mice…

Pharmacology

Acetaminophen (APAP) & the ECS: A Surprising New Twist in How Tylenol Really Works

Posted on May 19, 2025May 19, 2025 By Stefan Broselid

New research upends our understanding of how acetaminophen (paracetamol) provides pain relief via the endocannabinoid system. Discover how it directly inhibits DAGLα, reducing 2-AG levels – a surprising twist on conventional ECS wisdom. Explore the implications for future drug development.